Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Hims & Hers Health (HIMS) Shares Spike with Compounded Drug Strategy for GLP-1s
Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...
Lilly, Novo expand DTC reach of obesity meds after compound win
Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions ...
News-Medical.Net2d
Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Zepbound copycats remain online despite FDA ban
Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re still available on some websites.
Eli Lilly (LLY) Leads India’s Weight-Loss Drug Race with Mounjaro
Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...
Chemistry World6dOpinion
Weight loss drug supply races
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...